

Financial news for CBRX dated on 2016-03-24: Juniper Pharmaceuticals Names Dr. Mary Ann Gray to Board

Financial news for CBRX dated on 2015-04-02: Columbia Laboratories to Become Juniper Pharmaceuticals

Financial news for CBRX dated on 2015-03-31: Top Performing Industries For March 31, 2015

Financial news for CBRX dated on 2015-03-30: Columbia Labs Reports Purchase of Exclusive Global License for Novel IVR Technology

Financial news for CBRX dated on 2015-03-18: Morning Market Losers

Financial news for CBRX dated on 2015-03-18: Columbia Labs Q4 EPS -\$0.05 vs \$0.07 est, May Not Compare

Financial news for CBRX dated on 2015-03-12: Columbia Labs Reports Federal Appeals Court Has Affirmed Dismissal of Class Action Suit

Financial news for CBRX dated on 2015-02-18: Top 4 Stocks In The Drug Delivery Industry With The Highest ROE

Financial news for CBRX dated on 2015-01-06: Columbia Labs Names Bridget Martell as Chief Medical Officer

Financial news for CBRX dated on 2015-01-06: Top 4 Small-Cap Stocks In The Drug Delivery Industry With The Highest Gross Margin

Financial news for CBRX dated on 2014-11-11: Top 4 Stocks In The Drug Delivery Industry With The Highest Revenue

Financial news for CBRX dated on 2014-10-30: Molecular Profiles To Launch US Strategic Alliance At AAPS

Financial news for CBRX dated on 2014-10-28: Columbia Laboratories, Inc. Reports Q3 EPS of \$0.34 Which May Not Compare \$0.12 Est; Revenue of \$11.50M Which May Not Compare \$9.74M Est

Financial news for CBRX dated on 2014-09-24: Columbia Labs Says Jonathan Lloyd Jones to Step Down, Names George Elston as CFO

Financial news for CBRX dated on 2014-09-08: Columbia Announces Completions of CRINONE License Renewal

Financial news for CBRX dated on 2014-08-06: Columbia Labs Reports Sale of IP, Technology for Legatrin PM, Will Receive \$2.2M

Financial news for CBRX dated on 2014-07-31: Columbia Laboratories, Inc. Reports Q2 EPS of \$0.01 Which May Not Compare \$0.11 Est; Revenue of \$6.90M Which May Not Compare \$8.71M Est; Cuts FY Sales Growth Guidance from 8-12% to 6-8%

Financial news for CBRX dated on 2014-07-17: Columbia Labs Reports Expanded IP Portfolio Amid Receipt of US Patent for Bioadhesive Progressive Hydration Tablets

Financial news for CBRX dated on 2014-04-30: Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest Revenue

Financial news for CBRX dated on 2014-04-29: Columbia Laboratories Reports Q1 EPS of \$0.01, Down 88% YOY; Revenue of \$7.25M, Up 9% YOY

Financial news for CBRX dated on 2014-03-07: US Stock Futures Edge Higher; All Eyes On Jobs Report

Financial news for CBRX dated on 2014-03-07: UPDATE: Columbia Laboratories Buys Back 1.4M Shares of Common Stock from Actavis at \$6.08/Share

Financial news for CBRX dated on 2014-03-07: Columbia Laboratories Buys Back 1.4M Shares Of Common Stock From Actavis

Financial news for CBRX dated on 2014-03-05: Columbia Laboratories Reports Q4 EPS of \$0.06 vs \$0.02 Est; Revenue of \$7.81M vs \$6.75M Est

Financial news for CBRX dated on 2013-11-14: Columbia Laboratories to Receive One-time Payment of \$300K from Actavis for CRINONE US Manufacturing Rights

Financial news for CBRX dated on 2013-10-23: Columbia Laboratories Announces Amended Class Action Lawsuit Dismissed without Prejudice

Financial news for CBRX dated on 2013-09-23: Columbia Laboratories' Molecular Profiles to Develop Topical & Oral Psoriasis Products for Telormedix

Financial news for CBRX dated on 2013-09-12: Morning Market Losers

Financial news for CBRX dated on 2013-09-12: Columbia Labs Buys Molecular Profiles for \$25M

Financial news for CBRX dated on 2013-08-26: Columbia Laboratories Regains Compliance with Nasdaq

Financial news for CBRX dated on 2013-08-07: Columbia Laboratories, Inc. Reports Q2 EPS of \$0.03 vs \$0.02 Est; Revenue of \$8.0M vs \$6.50M Est

Financial news for CBRX dated on 2013-07-26: Columbia Laboratories' Board Approves 1-for-8 Reverse Stock Split

Financial news for CBRX dated on 2013-05-09: Columbia Laboratories, Inc. Reports Q1 EPS of \$0.01 vs \$0.03 Est; Revenue of \$6.30M vs \$6.50M Est

Financial news for CBRX dated on 2013-04-09: A Peek Into The Market Before The Trading Starts

Financial news for CBRX dated on 2013-04-09: Columbia Laboratories Amends License Agreement with Merck Serono for CRINONE Ex-US to 2020

Financial news for CBRX dated on 2013-03-14: Columbia Laboratories, Inc. Reports Q4 EPS of \$0.01 vs \$0.02 Est; Revenue of \$7.10M vs \$7.60M Est

Financial news for CBRX dated on 2013-03-14: Earnings Scheduled For March 14, 2013

Financial news for CBRX dated on 2013-03-06: Columbia Labs Extends Holder Rights Plan to Preserve Use of Net Oper. Loss

Financial news for CBRX dated on 2013-03-06: Columbia Laboratories Extends Stockholder Rights Plan

Financial news for CBRX dated on 2013-01-16: Jonathan B. Lloyd Jones Named of Columbia Laboratories CFO

Financial news for CBRX dated on 2012-11-08: From Earlier: Columbia Laboratories Reports Q3 EPS \$0.00 vs \$0.01 Est; Revenues \$6.7M vs \$7.00M Est

Financial news for CBRX dated on 2012-10-26: Columbia Laboratories Confirms FDA Denies Watson's Appeal Related to Prochieve NDA for the Prevention of Preterm Birth

Financial news for CBRX dated on 2012-10-25: Columbia Laboratories Receives Nasdaq Non-compliance Letter

Financial news for CBRX dated on 2012-08-09: The Benchmark Company Maintains Columbia Laboratories at Speculative Buy, Raises PT to \$2

Financial news for CBRX dated on 2012-08-08: Columbia Laboratories Reports Q2 EPS \$0.02 vs \$0.00 Est; Revenues \$7.4M vs \$5.70M Est

Financial news for CBRX dated on 2012-03-13: A Peek Into The Market Before The Trading Starts

Financial news for CBRX dated on 2012-03-13: Columbia Laboratories Hires Cowen and Company to Assist in Evaluating Potential Strategic Transactions

Financial news for CBRX dated on 2012-03-06: Columbia Advised It No Longer Meets NASDAQ Listing Requirements

Financial news for CBRX dated on 2012-02-27: Morning Social Media Outlook for Monday Feb 27 (LNG, CBRX, OME, LUV)

Financial news for CBRX dated on 2012-02-27: A Peek Into The Market Before The Trading Starts

Financial news for CBRX dated on 2012-02-27: Financial Breakfast: Morning News Summary for February 27, 2012

Financial news for CBRX dated on 2012-02-27: Watson Receives Complete Response Letter from FDA for Progesterone Vaginal Gel 8%; Says Gel is Reducing Risk, but Did Not Meet The Level of Statistical Significance

Financial news for CBRX dated on 2012-02-13: Financial Breakfast: Morning News Summary for February 13, 2012

Financial news for CBRX dated on 2012-02-13: A Peek Into The Market Before The Trading Starts

Financial news for CBRX dated on 2012-02-13: Columbia Laboratories Transfers NDA for Progesterone Vaginal Gel 8% to Watson Pharmaceuticals

Financial news for CBRX dated on 2012-01-23: Benzinga's Microcap Movers for Monday January 23, 2012

Financial news for CBRX dated on 2012-01-23: Market Losers

Financial news for CBRX dated on 2012-01-23: Columbia Labs Plummet after Recommendation Denial by FDA

Financial news for CBRX dated on 2012-01-23: UPDATE: Benchmark Lowers PT on Columbia Laboratories, Maintains Speculative Buy

Financial news for CBRX dated on 2012-01-20: FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length

Financial news for CBRX dated on 2012-01-20: UPDATE: FDA Panel Votes 13 No 4 Yes on Columbia Labs Progesterone Gel on Risk Benefit

Financial news for CBRX dated on 2012-01-20: UPDATE: FDA Panel Votes 13 No 4 Yes on Columbia Labs Progesterone Gel on Efficacy

Financial news for CBRX dated on 2012-01-20: FDA Panel Votes 13 No 4 Yes on Columbia Labs Progesterone Gel on Efficacy

Financial news for CBRX dated on 2012-01-20: PREVIEW: Columbia Laboratories FDA Advisory Committee Meeting Begins at 8am EST

Financial news for CBRX dated on 2012-01-20: Columbia Laboratories Halted; Pending News

Financial news for CBRX dated on 2012-01-17: FDA Spokesperson: Meeting on Columbia's Pre-Term Birth Gel is Set for January 20th

Financial news for CBRX dated on 2012-01-17: FDA Spokesperson: Cannot Confirm or Deny FDA Review on Watson/Columbia Pre-Term Birth Gel; States Proprietary Info

Financial news for CBRX dated on 2012-01-17: Columbia Laboratories Trading 54.6% Lower on Heavy Volume; Currently at \$1.09

Financial news for CBRX dated on 2012-01-17: Columbia Laboratories Spokesperson Not Commenting on FDA Review on Pre-Term Birth Gel; Says Review Material Not Available Yet

Financial news for CBRX dated on 2012-01-17: KV Pharmaceutical Strength Likely Attributed to Columbia Labs Weakness in FDA Review

Financial news for CBRX dated on 2012-01-17: Columbia Labs Halted, Circuit Breaker

Financial news for CBRX dated on 2012-01-17: Watson Pharma and Columbia Labs Plunge on Proposed FDA Review

Financial news for CBRX dated on 2012-01-17: Columbia Laboratories Resumes Trading

Financial news for CBRX dated on 2012-01-17: Columbia Laboratories Halted for Circuit Breaker

Financial news for CBRX dated on 2012-01-17: UPDATE: FDA Reviewers Saying Columbia and Watson Did not Demonstrate Statistically Significant Efficacy in U.S. Subjects for Pre-Term Birth Gel -Reuters

Financial news for CBRX dated on 2012-01-17: FDA Reviews Columbia Laboratories and Watson Pharmaceuticals' Pre-Term Birth Gel -Reuters

Financial news for CBRX dated on 2011-12-14: Meta-analysis of Five Clinical Trials including Columbia Laboratories' PREGNANT Study Published in American Journal of Obstetrics and Gynecology

Financial news for CBRX dated on 2011-11-10: Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA

Financial news for CBRX dated on 2011-11-04: The Benchmark Company Maintains Buy Rating and \$7 PT on Columbia Laboratories

Financial news for CBRX dated on 2011-10-31: The Benchmark Company Maintains Speculative Buy Rating and \$7 PT on Columbia Laboratories

Financial news for CBRX dated on 2011-09-02: Benchmark Upgrades Columbia Laboratories To Speculative Buy, \$7 PT

Financial news for CBRX dated on 2011-07-27: Columbia Laboratories Licenses STRIANT Canadian Trademark and Marketing Rights to Invaron Pharmaceuticals Inc.

Financial news for CBRX dated on 2011-06-27: A Peek Into The Market Before The Trading Starts

Financial news for CBRX dated on 2011-06-27: Columbia Laboratories NDA for PROCHIEVE Gel Accepted for Filing by FDA

Financial news for CBRX dated on 2011-06-24: Columbia Laboratories Added to Russell 3000 Index

Financial news for CBRX dated on 2011-04-25: Hot Stocks to Buy on 4/25/11 and April 26, 2011- TZOO, NWD, JKS, SHZ, SINA, BIIB, CSNHD...

Financial news for CBRX dated on 2011-04-20: Actient Pharmaceuticals LLC Acquires U.S. Rights to STRIANT (CBRX)

Financial news for CBRX dated on 2011-04-07: Benchmark Comments On Columbia Laboratories Pregnant Study Results

Financial news for CBRX dated on 2011-04-06: Trading Resumes: Columbia Laboratories (CBRX)

Financial news for CBRX dated on 2011-04-06: Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE Vaginal Progesterone Gel Study Results

Financial news for CBRX dated on 2011-04-06: Columbia Laboratories Halted (CBRX)

Financial news for CBRX dated on 2011-03-11: Benchmark Reports Columbia Labs' Q4 Pro-Forma Beats Forecasts

Financial news for CBRX dated on 2011-02-28: Stock on The Move: (CBRX) Breaking out New High Flag Formation

Financial news for CBRX dated on 2010-12-07: Watson's Prochieve Achieves Target - Analyst Blog

Financial news for CBRX dated on 2010-12-07: Watson's Prochieve Achieves Target - Analyst Blog

Financial news for CBRX dated on 2010-12-06: Morning Market Movers (NEWL, VRGY, CBRX, PNBC)

Financial news for CBRX dated on 2010-10-05: Coverage Initiated For Columbia Labs

Financial news for CBRX dated on 2010-06-01: Early Volume Plays Among Those Valued Below \$10 (BEAT, OREX, ONCY, CBRX)

Financial news for CBRX dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?